Key result
Dual anti-platelet therapy reduced the recurrence of ischemic stroke or TIA compared to single anti-platelet therapy (OR 0.59) in patients with symptomatic intracranial arterial stenosis.
Why the study?
Direct comparisons between all secondary prevention strategies for intracranial arterial stenosis are lacking, particularly between single and dual antiplatelet therapies.
Does DAPT reduce the recurrence of ischemic stroke/TIA in patients with symptomatic ICAS compared to SAPT, DAPT+ET, or OAC?
Population
Patients with symptomatic ICAS across 5 trials
Comparison
DAPT vs SAPT, anticoagulant treatment, or ET
Design
Systematic review and Bayesian network meta-analysis
Authors
Loading...
DAPT merits first-line consideration for secondary prevention in symptomatic ICAS; strengthens meta-analytic support for dual over single antiplatelet therapy.
Meta-Analysis (n=2,159)
Does DAPT reduce the recurrence of ischemic stroke/TIA in patients with symptomatic ICAS compared to SAPT, DAPT+ET, or OAC?
Odds Ratio: 0.59 (95% CI 0.39–0.9)
DAPT is more effective than SAPT and DAPT+ET for secondary stroke prevention in patients with symptomatic intracranial arterial stenosis, without increasing hemorrhage risk compared to SAPT.
Reale et al. (2022) conducted a meta-analysis in Symptomatic intracranial arterial stenosis (ICAS) (n=2,159). Dual anti-platelet therapy (DAPT) vs. Single anti-platelet therapy (SAPT) was evaluated on Early recurrence of ischemic stroke or TIA (OR 0.59, 95% CI 0.39-0.90). Dual anti-platelet therapy reduced the recurrence of ischemic stroke or TIA compared to single anti-platelet therapy (OR 0.59) in patients with symptomatic intracranial arterial stenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: